Literature DB >> 11974449

Effects of angle Class II, division 1 treatment with jumping-the-bite appliances. A longitudinal study.

Jörg A Lisson1, Joachim Tränkmann.   

Abstract

AIM: The present study investigated treatment effects in patients with Angle Class II, Division 1 malocclusions treated with jumping-the-bite appliances on the basis of cast evaluation and lateral cephalometrics.
RESULTS: A significant reduction in overjet (p < 0.001) and overbite (p < 0.01) occurred during the course of treatment. A significant reduction in the SNA-angle (p < 0.001) and increase in the SNB-angle (p < 0.001) led to a reduced ANB-angle (p < 0.001). The treatment effect on the maxilla was greater than on the mandible. A slight posterior rotation of the maxilla (p < 0.05) occurred whereas the other vertical relations did not change significantly. The upper incisors were significantly retruded (p < 0.001) while the lower incisors were increasingly protruded (p < 0.001). The interincisal angle was not markedly altered.

Entities:  

Mesh:

Year:  2002        PMID: 11974449     DOI: 10.1007/s00056-002-0048-y

Source DB:  PubMed          Journal:  J Orofac Orthop        ISSN: 1434-5293            Impact factor:   1.938


  3 in total

1.  Changes in soft-tissue profiles after treatment of class II/1 patients with bite-jumping appliances.

Authors:  Jörg Alexander Lisson; Kay Mokrys; Gero Stefan Michael Kinzinger; Bettina Glasl; Björn Ludwig
Journal:  J Orofac Orthop       Date:  2013-03-07       Impact factor: 1.938

2.  Mandibular fossa morphology during therapy with a fixed functional orthodontic appliance : A magnetic resonance imaging study.

Authors:  Gero Stefan Michael Kinzinger; Jan Hourfar; Cornelia Kober; Jörg Alexander Lisson
Journal:  J Orofac Orthop       Date:  2018-02-20       Impact factor: 1.938

3.  A prospective controlled evaluation of Class II division 1 malocclusions treated with fixed lingual mandibular growth modificator.

Authors:  Osama H Alali
Journal:  Angle Orthod       Date:  2013-08-29       Impact factor: 2.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.